Related Experiment Video
Updated: Feb 24, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
Published on: March 30, 2014
Cholesterol Screening and Statin Prescription is Low Among HIV-Infected Patients on Protease-Inhibitor Regimens in
M Mosepele1, V Letsatsi2, L Mokgatlhe3
1Faculty of Medicine, University of Botswana, Gaborone, Botswana.
Insights
In Botswana, HIV patients on protease inhibitors (PIs) showed low cholesterol screening rates and statin use, despite many qualifying for treatment. This indicates a significant gap in cardiovascular disease (CVD) risk management.
Area of Science:
- Public Health
- HIV Medicine
- Cardiology
Background:
- Limited data exists on statin use for cardiovascular disease (CVD) risk reduction in HIV-infected patients on protease inhibitors (PIs) in sub-Saharan Africa (SSA).
- Cardiovascular risk management is crucial for HIV patients, especially those on specific antiretroviral therapies.
Purpose of the Study:
- To assess cholesterol screening and statin utilization among HIV-infected patients on PIs in Botswana.
- To evaluate the gap between statin indication and prescription for CVD risk reduction in this population.
Main Methods:
- Retrospective analysis of HIV-infected patients on PIs from 2008-2012 at a Botswana HIV clinic.
- Calculation of annual cholesterol screening proportions.
- Assessment of statin indication using 2012 Atherosclerosis CVD (ASCVD) and Framingham Risk Score (FRS) guidelines.
Main Results:
- Annual cholesterol screening increased from 19-30% (2008-2011) to 80% post-enrollment.
- In 2012, 31% of patients had hypercholesterolemia (> 5.0 mmol/L).
- Fewer than 1% were on statins, yet 14.3% (ASCVD) and 9.4% (FRS) met criteria for statin therapy.
Conclusions:
- A significant gap exists in prescribing statins to indicated HIV patients on PIs in Botswana.
- There is a critical need to improve CVD risk management strategies for this vulnerable population.
- Initiating statin therapy for eligible patients could reduce future cardiovascular events.
Background:
Little is known about the use of statin for cardiovascular disease (CVD) risk reduction among HIV-infected patients on protease inhibitors (PI`s) in sub-Saharan Africa (SSA).
Objective:
Cholesterol screening and statin use were retrospectively assessed among HIV-infected participants on PI`s between 2008 and 2012 at a large urban HIV clinic in Botswana.
Methods:
Proportion of participants screened per year was calculated and statin indication was assessed using atherosclerosis CVD (ASCVD) and Framingham risk (FRS) scores as of the year 2012 guidelines.
Results:
Cholesterol screening ranged between 19% and 30% per year (2008-2011) but increased to 80% after study enrollment. The rate of hypercholesterolemia (> 5.0 mmol/L) was 31% in 2012. Fewer than 1% participants were on statin therapy but 14.3% and 9.4% had statins indicated by ASCVD and FRS respectively.
Conclusion:
The high proportion of participants indicated for, but not prescribed statins highlights a substantial gap in the care to reduce CVD risk among these patients.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Retrovirus Life Cycles
Cholesterol: Significance and Regulation
Considering cholesterol and...
Sexually Transmitted Infections

